Farooqui, M. Z. H., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., . . . Wiestner, A. (2014). Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial. Lancet Oncol.
Chicago-stil citatFarooqui, Mohammed Z H., et al. "Ibrutinib for Previously Untreated and Relapsed or Refractory Chronic Lymphocytic Leukaemia With TP53 Aberrations: A Phase 2, Single-arm Trial." Lancet Oncol 2014.
MLA-referensFarooqui, Mohammed Z H., et al. "Ibrutinib for Previously Untreated and Relapsed or Refractory Chronic Lymphocytic Leukaemia With TP53 Aberrations: A Phase 2, Single-arm Trial." Lancet Oncol 2014.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.